Family-organized groups are planning a number of meetings in 2019 for individuals with rare genetic neurodevelopmental conditions, including those due to 16p11.2 copy number variants and mutations in ASXL3, PACS1, PPP2R5D, SCN2A and STXBP1 single genes. SFARI can help to facilitate research opportunities at these meetings by connecting investigators with families.
SFARI is pleased to announce that it expects to have funded 22 grants in response to the Explorer Awards request for applications (RFA) this year.
Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials) — a European initiative to study autism — has launched The Innovative Medicines Initiative, a European public-private initiative, recently awarded a €115 million five-year grant for autism research. The Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials) brings together 48 partners from academia, industry and nonprofit foundations, including SFARI.
Simons Variation in Individuals Project (Simons VIP): New data release New Simons VIP Phase 2 data were recently added to SFARI Base. This data release included data from individuals with 16p11.2 copy number variants, 1q21.1 CNVs and mutations in the following single genes: ADNP, ASXL3, CHAMP1, CHD8, CSNK2A1, DYRK1A, GRIN2B, HIVEP2, HNRNPH2, MED13L, PACS1, PPP2R5D,…
Neuroscience 2018: Presentations by SFARI Investigators SFARI Investigators will be giving a number of presentations at Neuroscience 2018 in San Diego, CA (November 3–7).
SFARI 2018 Pilot and Research awardees announced SFARI is pleased to announce that it intends to fund 36 grants (15 Pilot Awards and 21 Research Awards) in response to the 2018 Pilot and Research Awards request for applications.